ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 256 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $509,795 | +2.3% | 14,300 | +32.4% | 0.01% | 0.0% |
| Q2 2023 | $498,204 | +25.5% | 10,800 | +9.1% | 0.01% | +25.0% |
| Q1 2023 | $396,990 | +53.0% | 9,900 | +76.8% | 0.00% | +33.3% |
| Q4 2022 | $259,448 | +2.7% | 5,600 | -8.2% | 0.00% | 0.0% |
| Q3 2022 | $252,601 | -66.9% | 6,100 | -41.9% | 0.00% | -57.1% |
| Q1 2022 | $763,000 | -34.7% | 10,500 | -24.5% | 0.01% | -12.5% |
| Q4 2021 | $1,169,000 | +5.4% | 13,900 | +13.0% | 0.01% | -27.3% |
| Q3 2021 | $1,109,000 | +14.0% | 12,300 | +20.6% | 0.01% | +10.0% |
| Q2 2021 | $973,000 | -17.8% | 10,200 | -1.9% | 0.01% | -16.7% |
| Q1 2021 | $1,184,000 | -0.5% | 10,400 | +20.9% | 0.01% | 0.0% |
| Q4 2020 | $1,190,000 | +281.4% | 8,600 | +126.3% | 0.01% | +200.0% |
| Q3 2020 | $312,000 | +42.5% | 3,800 | +35.7% | 0.00% | +33.3% |
| Q2 2020 | $219,000 | – | 2,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |